New formulation provides patients with a simplified dosing experience—reducing pill burden and enhancing ease of administration—while preserving flexible dosing options SAN CARLOS, Calif., June 11, ...

FOSTER CITY, Calif., April 14, 2025--(BUSINESS WIRE)--Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM) today announced that the U.S. Food and Drug Administration (FDA) has approved a new tablet formulation ...

Zanubrutinib's new tablet formulation is approved for all five indications, reinforcing its market leadership among BTK inhibitors. The 160 mg tablet simplifies dosing, reducing the daily intake from ...

The US Food and Drug Administration (FDA) has granted approval to a tablet formulation of BeOne Medicines’ targeted cancer drug Brukinsa (zanubrutinib). The company formerly known as BeiGene announced ...

BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced that the European Commission has approved a new film-coated tablet formulation of BRUKINSA ® ...

The approval was based on data from the phase 1 ELEVATE-PLUS trials, which showed the acalabrutinib 100mg tablets were bioequivalent to the acalabrutinib 100mg capsules. The Food and Drug ...

Roche has announced that a tablet formulation of its spinal muscular atrophy (SMA) treatment Evrysdi (risdiplam) has been approved by the US Food and Drug Administration (FDA). Evrysdi was originally ...

Protein formulation specialists have long sensed that something big could be just around the corner. Over the past few decades, countless companies have attempted to bring to market new protein ...

Formulation development is one of the critical steps in advancing a protein or a peptide as a therapeutic product. The challenge is to maintain the integrity of the complex and the often highly ...

New formulation provides patients with a simplified dosing experience-reducing pill burden and enhancing ease of administration-while preserving flexible dosing options BeOne Medicines Ltd. (NASDAQ: ...